Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long- Term Incidence of Clinical Cardiotoxicity in Women with Breast Cancer, a prospective randomised study: The Cardio-Oncology Breast Cancer Study.

Trial Profile

Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long- Term Incidence of Clinical Cardiotoxicity in Women with Breast Cancer, a prospective randomised study: The Cardio-Oncology Breast Cancer Study.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2018

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms COBC
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Mar 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
    • 06 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top